Auro Vaccines LLC
VesiculoVax - Preclinical-Stage Prophylactic Vaccines for Lassa Virus
Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against Lassa hemorrhagic fever.
Most popular related searches
vaccination
vaccination candidate
vaccine candidate
vaccine development
infectious disease emergency
health based
disease virus
vaccine efficacy
vaccine program
clinical phase
Program Status:
The vaccine candidate has demonstrated efficacy in a non-human primate challenge and has completed IND-enabling toxicology studies. The program has been out-licensed to Emergent BioSolutions and is scheduled to enter Phase I clinical evaluation in 2021.
Unmet Medical Need:
This rodent-borne virus infects up to 3 million humans per year in West Africa. Public health concern is based on both the emerging infectious disease status of this virus and its potential use as a biologic weapon.